

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IMPACT Therapeutics, Inc
南京英派藥業股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock code: 7630)

VOLUNTARY ANNOUNCEMENT

**IMP1734 PHASE 1/2 CLINICAL DATA PRESENTED
AT 2026 ASCO ANNUAL MEETING**

This announcement is made by IMPACT Therapeutics, Inc (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the latest business updates of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the latest Phase 1/2 clinical data for its highly selective PARP1 inhibitor, IMP1734 (also known as EIK1003), were presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held from May 29 to June 2, 2026, in Chicago, USA. The poster (Abstract #3102) featured data on the safety and preliminary efficacy of IMP1734 both as monotherapy and in combination with paclitaxel for the treatment of advanced solid tumors.

Detailed information on this study selected for ASCO 2026 is as follows:

Title: EIK1003 (IMP1734), A PARP1-Selective Inhibitor, in Combination with Paclitaxel: Initial Combination and Updated Monotherapy Results from a Phase 1/2 Study EIK1003-001 in Advanced Solid Tumors

Key Highlights:

Updated Results from IMP1734 Monotherapy (Cohort 1A)

Among 49 efficacy-evaluable patients with advanced solid tumors, the objective response rate (ORR) was 14.3%; all 7 responses were partial responses (PR). The disease control rate (DCR) was 38.8%. For confirmed responders, the median duration of response (DOR) was 7.8 months (range: 6.0-15.9+ months). In PARP inhibitor-naïve patients, the ORR was 26.7%. The safety profile was consistent with prior data and was generally favorable.

Results from IMP1734 in Combination with weekly Paclitaxel (Cohort 1C)

Among 53 efficacy-evaluable patients, the ORR was 24.5%, including 1 confirmed complete response (CR) and 12 partial responses (PR). Of these responders, 92% had prior taxane exposure, indicated that the antitumor activity was observed despite prior taxane exposure. By tumor type, the ORR was 29.6% in patients with epithelial ovarian cancer and 19.2% in patients with HER2-breast cancer. IMP1734 + weekly paclitaxel showed a manageable safety profile in an advanced-line population, with Grade ≥ 3 TEAEs occurring in 75.0% of patients. The most common Grade ≥ 3 TEAEs were neutropenia (50.0%) and anemia (13.3%). All 8 participants who developed Grade ≥ 3 anemia had Grade 1-2 anemia at baseline. No unexpected safety signals were observed, and the hematologic toxicity profile was manageable in this heavily pre-treated population and in line with the effects of the weekly paclitaxel.

Conclusion: IMP1734 monotherapy demonstrated durable antitumor activity and a favorable safety profile in a heavily pre-treated patient population with HRR-mutated advanced solid tumors. The clinical data for IMP1734 in combination with weekly paclitaxel provided the first clinical evidence that a PARP1-selective inhibitor can be safely combined with cytotoxic chemotherapy, thereby enabling a combination approach that was previously not feasible with non-selective PARP inhibitors.

ABOUT IMP1734

IMP1734 is a novel PARP1-selective inhibitor with high potency of inhibiting PARP1 and low activity of inhibiting PARP2. Preclinical in vivo models demonstrated high anti-tumor activities and a wide therapeutic window. The improved therapeutic index of IMP1734 over currently marketed non-selective PARP1/2 inhibitors supports its development as monotherapy and in combination with other agents. Overall, phase I studies demonstrated relatively low rates of hematologic toxicity, and clinical activity was observed at most doses tested, as evidenced by target lesion size reduction and durable responses. In addition, tolerability and efficacy are being evaluated in combination with Abiraterone and Paclitaxel, respectively, and results of these combination studies will be disclosed at future medical meetings. Additional information about the clinical trials of IMP1734 can be found at <https://clinicaltrials.gov/study/NCT06253130>.

In May 2023, the Company and Eikon Therapeutics, Inc. (“**EIKON**”) entered into an exclusive global licensing and collaboration agreement. Under the agreement, EIKON holds the exclusive rights to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1-selective inhibitors in all territories outside of Greater China.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that IMP1734 will ultimately be successfully developed and marketed. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
IMPACT Therapeutics, Inc
Dr. Sui Xiong CAI
Executive Director and Chief Executive Officer

Hong Kong, June 1, 2026

As at the date of this announcement, the Board comprises (i) Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA as executive directors; (ii) Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU as non-executive directors; and (iii) Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO as independent non-executive directors.